2025 Perinatal Grand Rounds

Advances in Screening, Diagnosis and Treatment of Congenital Cytomegalovirus

Cytomegalovirus (CMV) is a common virus that can lead to adverse childhood health outcomes when a fetus is infected during pregnancy. Strong parent advocacy and recent developments in screening, diagnosis and treatment are improving recognition and prevention of this perinatal viral infection. This presentation will provide and up-to-date overview of congenital CMV.

Register to unlock the course, then click ‘Continue.’ Course materials are available at the bottom of this page.
Write your awesome label here.
Patrick Jones - Course author
Meet the instructor

Elizabeth Goetz, MD, MPH

Elizabeth Goetz is a pediatrician and newborn hospitalist at Meriter Hospital/UW Madison. For the last 2 years, Dr. Goetz has been working to increase awareness of congenital cytomegalovirus in the state of Wisconsin.


The speaker has no relevant financial relationships with ineligible companies.*

Learning Outcomes

At the conclusion of this activity, participants will be able to:
  • Describe the clinical presentation of cCMV.
  • List three screening approaches for cCMV.
  • Develop a diagnostic work-up and follow-up plan for babies with a positive CMV screening test.
  • Discuss five ways to prevent perinatal transmission of CMV.

Accreditation Statement

Continuing Medical Education

The Wisconsin Association for Perinatal Care (WAPC) is accredited by the Wisconsin Medical Society to provide continuing medical education for physicians.

The Wisconsin Association for Perinatal Care (WAPC) designates this internet enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Course Content

Planning Committee

No one in control of content has any relevant financial relationships with ineligible companies.*

Course Information

This webinar was recorded on 18 September 2025.

The expiration date for this course is 06 October 2028.


*Ineligible companies are those whose primary business in producing, marketing, selling, reselling, or distributing health care products used by or on patients.